글로벌 원발성 경화성 담관염 시장 – 2028년까지의 산업 동향 및 예측

원발성 경화성 담관염 시장의 시장 분석 및 통찰력

간 질환의 유병률 증가와 알코올 소비 증가는 원발성 경화성 담관염 시장 성장에 기인합니다. Data Bridge Market Research는 원발성 경화성 담관염이 2021-2028년 예측 기간 동안 약 4.02%의 CAGR을 보일 것이라고 분석합니다.

원발성 경화성 담관염은 담관에 영향을 미치는 드문 질환입니다. 원발성 경화성 담관염에서는 담관이 흉터가 생깁니다. 이는 간 기능에 영향을 미칩니다. 즉, 원발성 경화성 담관염은 간과 담낭에 영향을 미치는 만성 질환입니다. 주로 30~50세 연령대 남성에게 나타납니다. 담관이 막혀 담즙산이 축적되고, 이는 간 조직을 손상시킵니다.

전 세계적으로 간 질환의 유병률이 증가함에 따라 원발성 경화성 담관염 시장이 성장하고 있습니다. 나쁜 생활 방식으로 인한 담즙암 사례가 증가함에 따라 원발성 경화성 담관염 시장도 성장하고 있습니다. 많은 수의 파이프라인 분자가 시장 성장을 더욱 촉진할 것으로 예상됩니다.

그러나 임상 후기 단계에서 분자를 철수하면 시장 성장이 방해받을 것입니다. 이 방향으로 인식을 확산하고 연구 개발 활동을 수행하기 위한 정부의 이니셔티브가 부족하면 성장 범위가 더욱 제한될 것입니다. 저소득 및 중산층 경제에서 이 분야의 숙련된 전문가나 훈련된 전문 지식이 부족하면 성장에 방해가 될 것입니다.

This primary sclerosing cholangitis market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on primary sclerosing cholangitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Primary Sclerosing Cholangitis Market Scope and Market Size

The primary sclerosing cholangitis market is segmented on the basis of type, treatment type, symptom control and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on the type, the primary sclerosing cholangitis market has been segmented into classic PSC, small-duct PSC and PSC associated with autoimmune hepatitis.
• On the basis of treatment type, the primary sclerosing cholangitis market is segmented into ursodeoxycholic acid, obeticholic acid, methotrexate, corticosteroids and others.
• On the basis of symptom control, the primary sclerosing cholangitis market is segmented into antihistamines, cholestyramine, antibacterials, opioid antagonists, colestipol and others.
• On the basis of end user, the primary sclerosing cholangitis market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.

Primary Sclerosing Cholangitis Market Country Level Analysis

The primary sclerosing cholangitis market is analysed and market size insights and trends are provided by country, type, treatment type, symptom control and end user as referenced above.

The countries covered in the primary sclerosing cholangitis market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the primary sclerosing cholangitis market owing to the prevalence of sophisticated healthcare infrastructure, increased research and development proficiencies by the pharmaceutical companies and rapid adoption of new and better healthcare technologies. Favourable reimbursement policies are also inducing the dominance of the region. Asia-Pacific on the other hand is projected to score highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure and rising prevalence of liver diseases and disorders.

The country section of the primary sclerosing cholangitis market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The primary sclerosing cholangitis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for clinical trial imaging market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the primary sclerosing cholangitis market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Primary Sclerosing Cholangitis Market Share Analysis

The primary sclerosing cholangitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to primary sclerosing cholangitis market.

주요 경화성 담관염 시장 보고서에 포함된 주요 업체는 Glenmark Pharmaceuticals Limited, Zydus Pharmaceuticals, Inc., Merck & Co., Inc., Sanofi, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited., F. Hoffmann-La Roche Ltd, Abbott, Teva Pharmaceutical Industries Ltd., Mylan NV, Sandoz International GmbH, Bristol-Myers Squibb Company, Amneal Pharmaceuticals LLC., HighTide Therapeutics Inc., Sirnaomics, Inc., Allergan, Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals 등입니다. 기타 국내 및 글로벌 업체도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-36313